177 related articles for article (PubMed ID: 16943522)
1. What is the right dose? The elusive optimal biologic dose in phase I clinical trials.
Adjei AA
J Clin Oncol; 2006 Sep; 24(25):4054-5. PubMed ID: 16943522
[No Abstract] [Full Text] [Related]
2. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.
Welch PA; Sinha VP; Cleverly AL; Darstein C; Flanagan SD; Musib LC
J Clin Pharmacol; 2007 Sep; 47(9):1138-51. PubMed ID: 17766700
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
Widmer N; Gotta V; Haouala A; Decosterd LA
Leuk Res; 2010 Jun; 34(6):698-9. PubMed ID: 20074797
[No Abstract] [Full Text] [Related]
5. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
[TBL] [Abstract][Full Text] [Related]
7. Enzastaurin.
Ma S; Rosen ST
Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
9. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose.
Judson IR
J Clin Oncol; 2008 Feb; 26(4):521-2. PubMed ID: 18235112
[No Abstract] [Full Text] [Related]
10. Edotecarin.
Denny WA
IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
[TBL] [Abstract][Full Text] [Related]
11. KS trial begins.
AIDS Patient Care STDS; 2000 Jun; 14(6):338. PubMed ID: 10897507
[No Abstract] [Full Text] [Related]
12. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR
Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
[No Abstract] [Full Text] [Related]
13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
15. [Early clinical trials in ECTG. Early Clinical Trial Group].
Ogawa M
Gan To Kagaku Ryoho; 1996 Jan; 23(2):238-41. PubMed ID: 8611053
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.
Benson C; Seger M; Voelker J
Clin Pharmacol Ther; 2007 Aug; 82(2):181-6. PubMed ID: 17443133
[TBL] [Abstract][Full Text] [Related]
17. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
De Giorgi U
J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
[No Abstract] [Full Text] [Related]
18. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
Saeki T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
[TBL] [Abstract][Full Text] [Related]
19. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
20. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Herbst RS; Oh Y; Wagle A; Lahn M
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
